Wealth Enhancement Advisory Services
CKPT

Wealth Enhancement Advisory Services’s Checkpoint Therapeutics CKPT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-426,100
Closed -$1.72M – 3402
2025
Q1 		$1.72M Buy
426,100
+1,100
+0.3% +$3.67K ﹤0.01% 1322
2024
Q4 		$1.36M Buy
425,000
+295,000
+227% +$1M ﹤0.01% 1381
2024
Q3 		$291K Buy
130,000
+80,000
+160% +$185K ﹤0.01% 2201
2024
Q2 		$108K Hold
50,000
– – ﹤0.01% 2401
2024
Q1 		$103K Sell
50,000
-35,000
-41% -$69.8K ﹤0.01% 2287
2023
Q4 		$195K Buy
85,000
+37,250
+78% +$81.1K ﹤0.01% 2094
2023
Q3 		$81.2K Buy
+47,750
New +$109K ﹤0.01% 2124

Wealth Enhancement Advisory Services's CKPT Position: Q2 2025 in Review

Wealth Enhancement Advisory Services sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 426,100 shares — an estimated $1.72M sold.

Wealth Enhancement Advisory Services first reported a position in CKPT in Q3 2023 and held it in 7 quarters. The position peaked at $1.72M in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.

  • Wealth Enhancement Advisory Services reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 426,100 Checkpoint Therapeutics shares in Q2 2025, an estimated $1.72M.
  • Wealth Enhancement Advisory Services first reported a position in Checkpoint Therapeutics in Q3 2023 and held it in 7 quarters.
  • Wealth Enhancement Advisory Services's Checkpoint Therapeutics position peaked at $1.72M in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2025, filed 10 Jul 2025.